FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Date/App# patent app List of recent Cytokine-related patents
01/29/15
20150031649
 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis patent thumbnailnew patent Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
Voltarra Pharmaceuticals, Inc.
01/29/15
20150031625
 Targeted vectors for cancer immunotherapy patent thumbnailnew patent Targeted vectors for cancer immunotherapy
This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject.
The University Of Southern California
01/29/15
20150030633
 Application of mrna for use as a therapeutic against tumour diseases patent thumbnailnew patent Application of mrna for use as a therapeutic against tumour diseases
The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh
01/29/15
20150030562
 Methods of treating or preventing viral diseases by blocking interleukin-21 patent thumbnailnew patent Methods of treating or preventing viral diseases by blocking interleukin-21
The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (il)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of immune cells in a mammal comprising administering to the mammal an il-21 blocking agent in an amount effective to reduce the activation or recruitment of immune cells in the mammal.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
01/22/15
20150025603
 Methods and  multi-vessel renal neuromodulation patent thumbnailMethods and multi-vessel renal neuromodulation
Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
01/22/15
20150025223
 System and  producing interleukin receptor antagonist (ira) patent thumbnailSystem and producing interleukin receptor antagonist (ira)
The present invention relates to a system and method for producing high levels of autologous il-1ra cytokine, comprising: a blood collection vessel (1), a cover (4), a portion of separation gel (2), an anticoagulant portion (3), a plasma collection syringe comprising a sharp needle (9), a buffy coat collection syringe (11) and an incubation tube with cover (15). The vessel is adapted such that, when containing the whole blood (5), and centrifuged after treatment, yields separation fractions comprising, a first fraction of rbcs sediment (6), a second fraction of said gel (2), a third fraction comprising wbcs, platelets and), and fourth fraction of plasma solution (8)..
Estar Technologies Ltd
01/22/15
20150025009
 Collagen and fibrin microthreads in a discrete thread model of in vitro acl scaffold regeneration patent thumbnailCollagen and fibrin microthreads in a discrete thread model of in vitro acl scaffold regeneration
Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute
01/22/15
20150024482
 Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer patent thumbnailCompositions and methods for generating a persisting population of t cells useful for the treatment of cancer
The present invention provides compositions and methods for generating a genetically modified t cells comprising a chimeric antigen receptor (car) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a cd3 zeta signaling domain, wherein the t cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.. .
The Trustees Of The University Of Pennsylvania
01/22/15
20150024459
 Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors patent thumbnailMultivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
Ibc Pharmaceuticals, Inc.
01/22/15
20150023990
 Alkoxy substituted imidazoquinolines patent thumbnailAlkoxy substituted imidazoquinolines
Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.. .
3m Innovative Properties Company
01/22/15
20150023980

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases


The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis a, b, c and other types of hepatitis, the diseases and conditions caused by hiv or associated with hiv, including aids.. .
01/22/15
20150023972

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases


The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis a, b, c and other types of hepatitis, the diseases and conditions caused by hiv or associated with hiv, including aids.. .
01/22/15
20150023909

Lymph node-targeting nanoparticles


Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. A cytokine.
Duke University
01/15/15
20150018821

Methods and intravascularly-induced neuromodulation


Methods and apparatus are provided for intravascularly-induced neuromodulation using a pulsed electric field, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation, etc., in target neural fibers. In some embodiments, the intravascular pef system comprises a catheter having a pair of bipolar electrodes for delivering the pef, with a first electrode positioned on a first side of an impedance-altering element and a second electrode positioned on an opposing side of the impedance-altering element.
Medtronic Ardian Luxembourg S.a.r.l.
01/08/15
20150011419

Systems and methods for characterizing lupus erythematosus


The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (sle) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of sle subjects for determining nephritic disease states and kidney damage in sle subjects and the efficacy of agents and interventions used to treat lupus nephritis..
Renovar, Inc.
01/08/15
20150010946

Polynucleotides encoding zcytor17 ligand antibodies


The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine.
Zymogenetics, Inc.
01/08/15
20150010630

Functionalization of biomaterials to control regeneration and inflammation responses


The inventions provided herein generally relate to compositions and methods for controlling response of immune cells to at least one stimulus or condition (e.g., but not limited to, tissue damage, an implantable device and/or a cytokine) in vitro or in vivo. The compositions described herein comprise a biomaterial (e.g., a silk fibroin-based matrix) comprising at least one immune cell-modulating agent in an effective amount sufficient to selectively alter activation state of at least one type of immune cells (e.g., but not limited to macrophages and dendritic cells).
Trustees Of Tufts College
01/08/15
20150010553

Methods of treating inflammatory diseases using antibodies that bind both il-17a and il-17f


The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease.
Zymogenetics, Inc.
01/08/15
20150010498

Immunocytokines for cancer treatment in combination with chemotherapeutic agents


This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (il2) conjugates which target tenascin-c.. .
Philogen S.p.a.
01/08/15
20150010497

Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors


The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies..
Bionest Ltd.
01/01/15
20150007357

Use of humanized mice to determine toxicity


The invention is directed to a method of determining whether an agent causes immune toxicity in a human comprising administering the agent to a non-human mammal that has been engrafted with human hematopoietic stem cells (hscs) and administered one or more human cytokines; and determining whether the agent causes immune toxicity in the non-human mammal. If the agent causes immune toxicity in the non-human mammal then the agent causes toxicity in a human.
Massachusetts Institute Of Technology
01/01/15
20150004184

Elastin digest compositions and methods utilizing same


The present invention provides compositions for the therapeutic and/or cosmetic treatment of elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of elastin that penetrate into the tissue to which it is applied.
Human Matrix Sciences, Llc
01/01/15
20150004180

Method for inducing a trif-bias


Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (agp) crx-547 to induce a trif-biased response in a human system, which results in reduced levels of myd88-dependent cytokines relative to the myd88-dependent cytokines induced by its diastereomer agp crx-527.. .
Glaxosmithkline Biologicals S.a.
01/01/15
20150004170

Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2


The present invention relates to biological and medical applications of an anti-cd160 monoclonal antibody (cl1-r2 cncm i-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-cd160 compounds in the fields of ec angiogenesis, and nk and t cytokine production..
Inserm (institut National De La Sante Et De La Recherche Medicale)
12/25/14
20140378395

Peptides for the treatment of hearing


Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and tnf-α secretion through interaction with toll-like receptor signaling pathways.
13therapeutics, Inc.
12/25/14
20140378371

Cytokine receptor peptides, compositions thereof and methods thereof


The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.
12/25/14
20140378347

Diagnostic test


Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention.
Meso Scale Technologies, Llc
12/25/14
20140377234

Methods of expanding myeloid cell populations and uses thereof


The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation..
Cellerant Therapeutics, Inc.
12/25/14
20140377227

Tissue transplantation involving, and tissues modified by decellularization and recellularization of donor tissues for minimized or obviated rejection reactions


The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (prp), the growth factors having increased weight..
12/25/14
20140377226

Tissue transplantation involving, and tissues modified by decellularization and recellularization of donor tissues for minimized or obviated rejection reactions


The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (prp), the growth factors having increased weight..
12/18/14
20140371299

Use of apoptosis-specific elf-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis


The present invention relates to apoptosis specific eucaryotic initiation factor 5a (eif-5a), referred to as apoptosis-specific eif-5a or eif5-a1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering sirna against eif-5a1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock.. .
Senesco Technologies, Inc.
12/18/14
20140370045

Use of the cd2 signaling domain in second-generation chimeric antigen receptors


The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified t cell expressing a car having an antigen binding domain, a transmembrane domain, a cd2 signaling domain, and a cd3 zeta signaling domain.
The Trustees Of The University Of Pennsylvania
12/18/14
20140370025

Uses of mammalian cytokines and agonists; related reagents


Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor..
Merck Sharp & Dohme Corp.
12/18/14
20140369957

Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors


The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies..
Bionest Ltd.
12/18/14
20140369927

Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases


Disclosed herein are compositions and methods of use comprising combinations of anti-cd22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-cd22 antibody or may be separately administered, either before, simultaneously with or after the anti-cd22 antibody.
Immunomedics, Inc.
12/11/14
20140363529

Compounds influencing fatty acid uptake and metabolism and methods of isolating from cocoa products


The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions.
12/11/14
20140363500

Use of an antibody and a particulate immunomodulator


The current invention is directed to particulate or vesicular immunomodulators, like e.g. Cytokines, for use in combination therapy with antibodies for treatments of a range of conditions and diseases, in particular cancer, as well as methods, compositions, and kits thereof..
12/11/14
20140363499

Use of a particulate immunomodulator in cancer therapy


The current invention is directed to a particulate or vesicular formulation of an immune modulating molecule, like e.g. Cytokines, as well as uses, methods, compounds thereof.
12/11/14
20140363456

Tumor-specific gm-csf cytokine response as predictor of cancer vaccine effectiveness


The present invention relates to methods of treating cancer with a cancer vaccine using granulocyte-macrophage colony-stimulating factor (gm-csf) as a biomarker; methods of prognosticating an outcome of cancer treatment with a cancer vaccine using gm-csf as a biomarker; methods for qualifying subjects for cancer vaccination using gm-csf as a biomarker; methods for comparing the efficacy of two or more cancer vaccine treatments based on gm-csf response; and kits for the effective treatment of cancer.. .
12/04/14
20140357936

Non-invasive treatment of neurodegenerative diseases


Methods and devices are disclosed for the non-invasive treatment of neurodegenerative diseases through delivery of energy to target nervous tissue, particularly the vagus nerve. The devices include a magnetic stimulator having coils with toroidal windings, which are in contact with an electrically conducting medium that is adapted to conform to the contour of a target body surface of a patient.
12/04/14
20140356373

Methods and compositions for treating lupus


The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, meisoindigo and natura in an amount sufficient to treat the lupus; preferably by modulating cytokine expression.
11/27/14
20140350527

"self-regulating device for modulating inflammation"


A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing.
11/27/14
20140350250

Therapeutic agent for cerebral infarction


The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-α, il-1β, il-6 and mcp-1 and the like..
11/27/14
20140350249

Therapeutic agent for cerebral infarction


The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-α, il-1β, il-6 and mcp-1 and the like..
11/27/14
20140348940

Amniotic membrane hydrogel and methods of making


The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta.
11/27/14
20140348789

Targeted mutant alpha-helical bundle cytokines


This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells.
11/27/14
20140348783

Vaccine immunotherapy for immune suppressed patients


A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348782

Vaccine immunotherapy for immune suppressed patients


A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.6718

3383

458899 - 0 - 76